Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ketamine + levobupivacaine
- Development stage
- Phase 4
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Paravertebral, Caudal, Intraarticular
01
Overview
A combination of ketamine and levobupivacaine used for local and regional anesthesia. Ketamine is an NMDA receptor antagonist that produces dissociative anesthesia and analgesia by decreasing the central nervous system's sensitivity to pain. Levobupivacaine is a local anesthetic that blocks sodium channels in peripheral nerves, preventing the transmission of pain signals. When used together, these drugs act synergistically on both central and peripheral components of the pain pathway, providing enhanced and prolonged pain relief with potentially fewer side effects than higher doses of either drug alone.
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)MOR (Mu opioid receptor)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on ketamine + levobupivacaine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ketamine + levobupivacaine.